Cargando…

Characterization of GLPG0492, a selective androgen receptor modulator, in a mouse model of hindlimb immobilization

BACKGROUND: Muscle wasting is a hallmark of many chronic conditions but also of aging and results in a progressive functional decline leading ultimately to disability. Androgens, such as testosterone were proposed as therapy to counteract muscle atrophy. However, this treatment is associated with po...

Descripción completa

Detalles Bibliográficos
Autores principales: Blanqué, Roland, Lepescheux, Liên, Auberval, Marielle, Minet, Dominique, Merciris, Didier, Cottereaux, Céline, Clément-Lacroix, Philippe, Delerive, Philippe, Namour, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4167280/
https://www.ncbi.nlm.nih.gov/pubmed/25185887
http://dx.doi.org/10.1186/1471-2474-15-291
_version_ 1782335404893011968
author Blanqué, Roland
Lepescheux, Liên
Auberval, Marielle
Minet, Dominique
Merciris, Didier
Cottereaux, Céline
Clément-Lacroix, Philippe
Delerive, Philippe
Namour, Florence
author_facet Blanqué, Roland
Lepescheux, Liên
Auberval, Marielle
Minet, Dominique
Merciris, Didier
Cottereaux, Céline
Clément-Lacroix, Philippe
Delerive, Philippe
Namour, Florence
author_sort Blanqué, Roland
collection PubMed
description BACKGROUND: Muscle wasting is a hallmark of many chronic conditions but also of aging and results in a progressive functional decline leading ultimately to disability. Androgens, such as testosterone were proposed as therapy to counteract muscle atrophy. However, this treatment is associated with potential cardiovascular and prostate cancer risks and therefore not acceptable for long-term treatment. Selective Androgen receptor modulators (SARM) are androgen receptor ligands that induce muscle anabolism while having reduced effects in reproductive tissues. Therefore, they represent an alternative to testosterone therapy. Our objective was to demonstrate the activity of SARM molecule (GLPG0492) on a immobilization muscle atrophy mouse model as compared to testosterone propionate (TP) and to identify putative biomarkers in the plasma compartment that might be related to muscle function and potentially translated into the clinical space. METHODS: GLPG0492, a non-steroidal SARM, was evaluated and compared to TP in a mouse model of hindlimb immobilization. RESULTS: GLPG0492 treatment partially prevents immobilization-induced muscle atrophy with a trend to promote muscle fiber hypertrophy in a dose-dependent manner. Interestingly, GLPG0492 was found as efficacious as TP at reducing muscle loss while sparing reproductive tissues. Furthermore, gene expression studies performed on tibialis samples revealed that both GLPG0492 and TP were slowing down muscle loss by negatively interfering with major signaling pathways controlling muscle mass homeostasis. Finally, metabolomic profiling experiments using (1)H-NMR led to the identification of a plasma GLPG0492 signature linked to the modulation of cellular bioenergetic processes. CONCLUSIONS: Taken together, these results unveil the potential of GLPG0492, a non-steroidal SARM, as treatment for, at least, musculo-skeletal atrophy consecutive to coma, paralysis, or limb immobilization. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2474-15-291) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4167280
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41672802014-09-19 Characterization of GLPG0492, a selective androgen receptor modulator, in a mouse model of hindlimb immobilization Blanqué, Roland Lepescheux, Liên Auberval, Marielle Minet, Dominique Merciris, Didier Cottereaux, Céline Clément-Lacroix, Philippe Delerive, Philippe Namour, Florence BMC Musculoskelet Disord Research Article BACKGROUND: Muscle wasting is a hallmark of many chronic conditions but also of aging and results in a progressive functional decline leading ultimately to disability. Androgens, such as testosterone were proposed as therapy to counteract muscle atrophy. However, this treatment is associated with potential cardiovascular and prostate cancer risks and therefore not acceptable for long-term treatment. Selective Androgen receptor modulators (SARM) are androgen receptor ligands that induce muscle anabolism while having reduced effects in reproductive tissues. Therefore, they represent an alternative to testosterone therapy. Our objective was to demonstrate the activity of SARM molecule (GLPG0492) on a immobilization muscle atrophy mouse model as compared to testosterone propionate (TP) and to identify putative biomarkers in the plasma compartment that might be related to muscle function and potentially translated into the clinical space. METHODS: GLPG0492, a non-steroidal SARM, was evaluated and compared to TP in a mouse model of hindlimb immobilization. RESULTS: GLPG0492 treatment partially prevents immobilization-induced muscle atrophy with a trend to promote muscle fiber hypertrophy in a dose-dependent manner. Interestingly, GLPG0492 was found as efficacious as TP at reducing muscle loss while sparing reproductive tissues. Furthermore, gene expression studies performed on tibialis samples revealed that both GLPG0492 and TP were slowing down muscle loss by negatively interfering with major signaling pathways controlling muscle mass homeostasis. Finally, metabolomic profiling experiments using (1)H-NMR led to the identification of a plasma GLPG0492 signature linked to the modulation of cellular bioenergetic processes. CONCLUSIONS: Taken together, these results unveil the potential of GLPG0492, a non-steroidal SARM, as treatment for, at least, musculo-skeletal atrophy consecutive to coma, paralysis, or limb immobilization. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2474-15-291) contains supplementary material, which is available to authorized users. BioMed Central 2014-09-03 /pmc/articles/PMC4167280/ /pubmed/25185887 http://dx.doi.org/10.1186/1471-2474-15-291 Text en © Blanqué et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Blanqué, Roland
Lepescheux, Liên
Auberval, Marielle
Minet, Dominique
Merciris, Didier
Cottereaux, Céline
Clément-Lacroix, Philippe
Delerive, Philippe
Namour, Florence
Characterization of GLPG0492, a selective androgen receptor modulator, in a mouse model of hindlimb immobilization
title Characterization of GLPG0492, a selective androgen receptor modulator, in a mouse model of hindlimb immobilization
title_full Characterization of GLPG0492, a selective androgen receptor modulator, in a mouse model of hindlimb immobilization
title_fullStr Characterization of GLPG0492, a selective androgen receptor modulator, in a mouse model of hindlimb immobilization
title_full_unstemmed Characterization of GLPG0492, a selective androgen receptor modulator, in a mouse model of hindlimb immobilization
title_short Characterization of GLPG0492, a selective androgen receptor modulator, in a mouse model of hindlimb immobilization
title_sort characterization of glpg0492, a selective androgen receptor modulator, in a mouse model of hindlimb immobilization
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4167280/
https://www.ncbi.nlm.nih.gov/pubmed/25185887
http://dx.doi.org/10.1186/1471-2474-15-291
work_keys_str_mv AT blanqueroland characterizationofglpg0492aselectiveandrogenreceptormodulatorinamousemodelofhindlimbimmobilization
AT lepescheuxlien characterizationofglpg0492aselectiveandrogenreceptormodulatorinamousemodelofhindlimbimmobilization
AT aubervalmarielle characterizationofglpg0492aselectiveandrogenreceptormodulatorinamousemodelofhindlimbimmobilization
AT minetdominique characterizationofglpg0492aselectiveandrogenreceptormodulatorinamousemodelofhindlimbimmobilization
AT mercirisdidier characterizationofglpg0492aselectiveandrogenreceptormodulatorinamousemodelofhindlimbimmobilization
AT cottereauxceline characterizationofglpg0492aselectiveandrogenreceptormodulatorinamousemodelofhindlimbimmobilization
AT clementlacroixphilippe characterizationofglpg0492aselectiveandrogenreceptormodulatorinamousemodelofhindlimbimmobilization
AT delerivephilippe characterizationofglpg0492aselectiveandrogenreceptormodulatorinamousemodelofhindlimbimmobilization
AT namourflorence characterizationofglpg0492aselectiveandrogenreceptormodulatorinamousemodelofhindlimbimmobilization